EBD Group: BIO-Europe 2010

EBD Group: BIO-Europe 2010

Speaking Engagement

As the preeminent emerging BRIC market, the buzz around partnering in China is building. China's rapidly growing drug market has become an essential focus for big pharma and biotech companies, and global collaborations already exist in R&D, manufacturing, commercialization as well as after sale services. Many overseas life science companies have started initiatives to increase their market share in China, and Chinese companies are developing new strategies for the domestic as well as international markets. Our panel of experts will address, from their personal and company perspectives, various aspects of how and why China is evolving so rapidly and what they see as key drivers for favorable partnering models as well as the challenges in such collaborations between Western and Chinese companies.

WilmerHale Partner and Co-Chair of the German Corporate Practice Group, Dr. Rüdiger Herrmann will serve as a panelist and WilmerHale China Liaison Officer, Alicia Hong will be the moderator for the panel session titled "Partnering Landscape in China."

Read More About the Event

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.